about
How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studiesActivity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study.Real-world study of everolimus in advanced progressive neuroendocrine tumors.Succinate dehydrogenase B subunit immunohistochemical expression predicts aggressiveness in well differentiated neuroendocrine tumors of the ileum.Compassionate use of everolimus in a patient with a neuroendocrine tumor: a case report and discussion of the literature.Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors.Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.Diagnosis and management of typical and atypical lung carcinoids.Treatment of lung large cell neuroendocrine carcinoma.Everolimus treatment in advanced solid tumors: a personal viewUpdate on medical treatment of small intestinal neuroendocrine tumors.Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.Safety profile and treatment response of everolimus in different solid tumors: an observational study.Everolimus treatment for neuroendocrine tumors: latest results and clinical potential.Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors.The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories.Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors.Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up.Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver.Well-differentiated neuroendocrine tumor of tailgut cyst. A rare entity with controversial medical opportunities.Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study.Pancreatic well-differentiated neuroendocrine neoplasms (pWDNENs): what place for everolimus and sunitinib derived from ESMO clinical practice guidelines in the therapeutic algorithm?Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives.The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer.Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors.Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin AnaloguesSunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world studyEverolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year UpdateEverolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group studyFatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancerFrom biology to clinical experience: evolution in the knowledge of neuroendocrine tumoursCapecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancerTreatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches.Sunitinib and everolimus in pancreatic neuroendocrine tumorsThe evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST
P50
Q26750748-C05E6FFC-9342-4C9F-B5E8-16832A644911Q33415304-BCBE385B-D302-470C-ADF9-B832C7355213Q33417013-35E0CCB3-6B01-4EDE-A255-8BDC5E019ADEQ37017036-44FFF90A-4846-4F4C-B1E7-E645F459638DQ37983576-20F0FE7D-5AAF-4BAD-B26E-A0F10F079D6FQ38544844-E8B8A70E-635C-48DC-AA1B-42D9B92E4B4EQ38674812-F0394E73-5A45-4ACF-88C3-4E53C1C332F1Q38738859-DD837AE3-7A84-48C8-9C2B-B0262AF0B0B6Q38751034-BC86AC96-5FDC-4808-BC96-E49863A9B728Q38760870-A161861C-102A-4016-A75C-F2294CE2B6CAQ38777011-E356CE4D-6775-4D91-B73F-6A65C74EACB0Q38879904-559CA0CC-A3E2-4D24-92A6-DF83FB748085Q38909078-F7770750-B17D-4A80-B05C-0B386FC00ECCQ39141798-644D7EAF-8578-4AB9-8B17-2A4AC41E4622Q39201601-8721F507-02ED-4BCC-8C5E-B28BCD36556DQ40447640-09DFFAA0-4661-49AC-BEE4-12B0C5664F05Q40499461-7036D315-47C9-4A4D-A35E-FE548A9EB3A8Q40975849-19809CC8-2EEC-4C7E-83A9-F513E106F1C6Q41236564-F26CA051-E473-4449-944F-6D9AD3B8F9F8Q42502987-A97CBC5F-FAB8-4FCC-A4FF-13EBDCBD0434Q45428270-0D134555-F879-4FB3-BCD0-B57D80494122Q46640564-30D1F6D0-AADD-4654-BB57-F5BF96FB9A37Q48278842-02072717-561A-4B04-ADF5-7C63661AE957Q51245559-FB109B5F-D730-42DF-A392-F7BF02B6D4C9Q51747406-247A3AA9-1976-4CFB-A8E7-3D1028063DD1Q52587886-A4EE6FBE-25B2-44F1-8069-BA3F546FF28EQ53827257-066477E5-CCC8-49A7-8C7F-83C32A41C063Q54582444-05BCD53A-C657-45FD-B030-47B6DA24EC5DQ55067415-051B5F5C-C4C3-4A18-B2B7-D2992746B540Q55460770-C3541C98-A25A-4200-8069-203DAE3191B7Q56354378-1326FE5C-BCE4-41D2-B68F-DA4EC5698360Q56927417-C6080912-9F6F-4B9C-A5A8-1B1115B2107CQ57102017-1DE2EFA5-6693-45EB-B2AA-0CC507952C92Q57109641-9CDCF103-30EE-47A9-A023-763586E709D9Q57763406-8BBDDDA5-2712-47E3-A936-160559905BEFQ58199990-FA4FB7BF-34CD-4198-B87D-06E49A626FAAQ61628340-2AD9FCFC-2A10-4C5C-8B2F-F0A88F43D120Q64930981-70BD41D7-CB88-432E-9E73-29AAE4F6EF63Q84605132-A43301F7-291D-481A-A8A3-D13C2E9BBFFDQ88530291-BD8C0B02-2D50-4218-9B0B-9F63233EDF4E
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sara Pusceddu
@ast
Sara Pusceddu
@en
Sara Pusceddu
@es
Sara Pusceddu
@nl
Sara Pusceddu
@sl
type
label
Sara Pusceddu
@ast
Sara Pusceddu
@en
Sara Pusceddu
@es
Sara Pusceddu
@nl
Sara Pusceddu
@sl
prefLabel
Sara Pusceddu
@ast
Sara Pusceddu
@en
Sara Pusceddu
@es
Sara Pusceddu
@nl
Sara Pusceddu
@sl
P1053
K-1064-2017
P106
P1153
24171479800
P21
P31
P3829
P496
0000-0002-5096-660X